GLP-1 Receptor Agonist Use and Incidence of Retained Gastric Food on Endoscopy

Medical University of South Carolina (MUSC)

Status: Completed

Conditions: Gastric Content Aspiration

Treatments: Other: Esophagogastroduodenoscopy

Study type: Observational

Funder types: Other

Identifiers

NCT05875636

Pro00129059

Details and patient eligibility

About

This study will enroll patients ages 18 and over who are in one of the following groups 1) taking a GLP-1 receptor agonist medication 2) not taking a GLP-1 receptor agonist (control group), are undergoing EGS and have appropriately fasted. Study data will be collected in the form of qualitatively observing whether the stomach is empty as expected, or contains solid or clinically relevant liquid contents.

Enrollment: 260 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

• Adults 18 years of age and older presenting for esophagogastroduodenoscopy (EGD)

• One of the following groups:

  • GLP-1 receptor agonist cohort: active treatment with any GLP-1 receptor agonist therapy within prior 30 days
  • Control cohort: not taking a GLP-1 receptor agonist medication

• Appropriately fasted per ASA Fasting Guidelines

Exclusion Criteria

• Simultaneous bowel preparation/planned dual endoscopy with colonoscopy
• Any pre-planned alteration to standard fasting guidelines (ASA NPO guidelines)
• Emergency endoscopic procedure
• Concern for active GI bleeding
• Food impaction/foreign body as indication for procedure
• Gastric outlet obstruction/bowel obstruction
• Achalasia
• Zenker's diverticulum
• History of esophageal or gastric surgery
• Active pregnancy
• Chronic daily opioid therapy ≥ 15 MMEs per day
• Prokinetic agent use (i.e. metoclopramide)
• Inability or unwillingness of subject to give informed consent

Trial design

260 participants in 2 patient groups

Patients taking a GLP-1 agonist medication

Description:

Participants meeting all inclusion/exclusion criteria who are taking a GLP-1 agonist medication

Treatment:

Other: Esophagogastroduodenoscopy

Controls

Description:

Participants meeting all inclusion/exclusion criteria and are NOT taking a GLP-1 agonist medication.

Treatment:

Other: Esophagogastroduodenoscopy